Methods: In 8/2009, a clinic devoted to managing HCV infection in cancer pts was started in our center by infectious diseases (ID) specialists in collaboration with hepatologists. Multidisciplinary educational activities were implemented to train nurses, mid-level providers, public health students, prospective internal medicine residents, ID fellows, and ID providers. To understand the strengths and limitations of diagnosis and management of this unique population and to establish best practices, all clinic pts were evaluated following a standardized approach.
Results: Between 8/2009 and 4/2015, 475 HCV-infected cancer pts were evaluated in the clinic. Pts were monitored for liver disease progression, eligibility for antiviral therapy (AVT), drug interactions, adverse events of AVT, and outcomes. Clinic nurses provided care to patients, facilitated insurance approval of treatment, assessed side effects of AVT, and educated pts/caregivers. Since 2009, 30 nurses have been trained and over 600 pts/caregivers educated on HCV infection. Seven mid-level providers were trained to deliver HCV care. In 2014, four ID fellows joined the clinic as an elective rotation. A formal training for managing HCV in cancer pts was begun in 2015 with a mandatory continuity clinic for ID fellows. Six research fellows have presented clinic data in more than 30 professional meetings, and published 15 articles in peer-reviewed journals including various aspects of epidemiology, oncogenesis, complications, and treatment outcomes. Future plans include evaluation of pt/caregivers knowledge and attitudes regarding HCV and AVT. Management guidelines are being developed for HCV-infected cancer patients related to rapidly changing standard of care.
Conclusion: Educational efforts focused on HCV care in cancer pts provide transdisciplinary
H. A. Torres,
P. Mahale, None
B. Granwehr, None
B. Blechacz, None
E. Miller, None
R. Borchardt, None
B. Shukla, None
C. Ericsson, None
I. Raad, UT MD Anderson Cancer Center: Shareholder , Licensing agreement or royalty
Novel Anti-Infective Technologies LLC: Shareholder , Licensing agreement or royalty